comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 23:31:09 - browse：3153

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Sutter Health’s antitrust win overturned by appeals court

focus

WSS

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Senators tussle over abortion against the backdrop of a presidential campaign

Obesity drugs seen as possible treatment for liver disease MASH

STAT wants to know your pick for a great summer read or listen

With competition flaring, obesity drug hits goal in liver disease study

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

leisure time

comprehensive

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

An outdated Medicare rule harms dementia patients with anxiety

Dobbs anniversary: the lost opportunity of abortion as health care

PBM reform efforts get punted in Congress

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Hepatitis C has a cure — but many Americans still lack access to it

STAT readers on older presidents, polypills, Medicare, and more

Continuity nursing helped my family in our darkest PICU moments

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

knowledge

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Data don't support strong claims for Covid

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Data don't support strong claims for Covid

With competition flaring, obesity drug hits goal in liver disease study

Obesity drugs seen as possible treatment for liver disease MASH

focus

hotspot

hotspot

knowledge